@article{edc2370960204d82ac92b486077bcb61,
title = "Response evaluation criteria in cancer of the liver (RECICL 2019 revised version)",
keywords = "Hepatocellular carcinoma response evaluation criteria in cancer of the liver, Liver cancer study group of Japan, Modified RECIST, RECIST",
author = "Masatoshi Kudo and Masafumi Ikeda and Kazuomi Ueshima and Michiie Sakamoto and Shuichiro Shiina and Ryosuke Tateishi and Kiyoshi Hasegawa and Junji Furuse and Shiro Miyayama and Takamichi Murakami and Tatsuya Yamashita and Norihiro Kokudo",
note = "Funding Information: 1）日本肝癌研究会．肝癌治療効果判定基準．肝臓 1994；35（2）：193―205 2）日本肝癌研究会．肝癌治療直接効果判定基準．肝臓 2004；45（7）：380―385 3）工藤正俊，久保正二，高安賢一，他．肝癌治療効果 判定基準（2009 年改訂版）．肝臓 2010；51（5）： 261―266 4）Kudo M, Kubo S, Takayasu K, et al. Response Evaluation Criteria in Cancer of the Liver (RE-CICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res 2010; 40: 686―692 5）日本肝癌研究会．「臨床・病理 原発性肝癌取扱い 規約」日本肝癌研究会編，第 6 版，金原出版，2015 6）工藤正俊，上嶋一臣，久保正二，他．肝癌治療効果 判定基準（2015 年改訂版）．肝臓 2015；56（3）： 116―121 7）Kudo M, Ueshima K, Kubo S, et al. Response Evalu-ation Criteria in Cancer of the Liver (RECICL) (2015 Revised version). Hepatol Res 2016; 46: 3―9 8）WHO handbook for reporting results of cancer treatment. Volume 48, World Health Organization Offset Publication, Geneva (Switzerland), 1979 9）Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Insti-tute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205―216 10）Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: re-vised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228―247 11）Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocel-lular carcinoma. AJR Am J Roentgenol 2000; 175: 699―704 12）Lencioni R, Llovet JM. Modified RECIST (mRE-CIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52―60 13）Arizumi T, Ueshima K, Takeda H, et al. Compari-son of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. J Gastroenterol 2014; 49: 1578―1587 14）Vincenzi B, Di Maio M, Silletta M, et al. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepato-cellular Carcinoma Patients Treated with Loco-Regional Therapies : A Literature-Based Meta-Analysis. PLoS One 2015; 10: e0133488 15）Meyer T, Palmer DH, Cheng AL, et al. mRECIST to predict survival in advanced hepatocellular car-cinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib. Liver Int 2017; 37: 1047―1055 16）Lencioni R, Montal R, Torres F, et al. Objective re-sponse by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 2017; 66: 1166―1172 17）Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic ar-terial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular car-cinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol 2018; 3: 424― 432 18）日本肝癌研究会．「臨床・病理 原発性肝癌取扱い 規約」日本肝癌研究会編，第 6 版補訂版，金原出版， 2019",
year = "2019",
month = feb,
day = "20",
doi = "10.2957/kanzo.60.55",
language = "English",
volume = "60",
pages = "55--62",
journal = "Acta Hepatologica Japonica",
issn = "0451-4203",
publisher = "Japan Society of Hepatology",
number = "2",
}
